Neuroscientific Biopharmaceuticals Ltd has released a press release.
CVN Model Indicates Neuroprotective Properties of EmtinB
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- NSB - Company Update
- AGM Address
- EmtinB Can Become a Revolutionary Treatment for Glaucoma
- NSB Receives R&D Advanced Overseas Finding
- NSB - FInal Data Received from Spinal Cord Injury Model
Later from Neuroscientific Biopharmaceuticals
- Additional US Patent granted
- Positive Results in Glaucoma Pig Model
- Positive Results in MS Study
- Final Report received for Glaucoma Study
- EmtinB Positive Results in MS
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals